At a glance
ClinicalIndex Comparison RecordN/ACompleted· 80 enrolled
Drug / intervention
Bifidobacterium, BB-12® (Bifidolactis Infant) +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Studio Clinico Randomizzato Per Valutare l'Efficacia Del Bifidobacterium BB-12® Nel Trattamento Delle Coliche Infantili
In Brief
A clinical study evaluating Bifidobacterium, BB-12® (Bifidolactis Infant) and Bifidolactis Infant Placebo for Infantile Colic and Colic, Infantile. Completed, enrolled 80 participants across 1 site.
Detailed Summary
This is a single-center, randomized, double blind controlled study to investigate the effects of Bifidobacterium, BB-12® versus placebo in a study group of pediatric patients with infantile colic.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfantile Colic, Colic, Infantile
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
Primary CompletionNov 2017
First PostedFeb 2018
TodayJul 2026
First PostedFeb 15, 2018
Enrollment StartNov 11, 2016
Primary CompletionNov 6, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 8.4 years ago
Interventions
Bifidobacterium, BB-12® (Bifidolactis Infant)dietary
Bifidolactis Infant Placebodietary